NeuroSense Therapeutics is in advanced discussions with major pharmaceutical companies for a potential partnership to develop and commercialize its ALS drug candidate, PrimeC. The company anticipates receiving terms for the partnership in the fourth quarter of 2024, based on promising Phase 2b trial data showing PrimeC’s efficacy in mitigating ALS progression and improving survival rates.